IceCure Medical (ICCM) Q4 2025 earnings review
FDA Clearance Ignites Record Revenue, But Cash Runway Remains a Major Risk
IceCure Medical finally secured its long-awaited FDA marketing clearance for low-risk breast cancer in Q4, and the impact was immediate: revenue surged to a record $1.3 million for the quarter, accounting for nearly 40% of its full-year sales. Furthermore, gross margins reversed their mid-year slump, rebounding to an estimated 47% in Q4 on higher volumes. However, executing a nationwide commercial rollout and a 400-patient post-marketing study is highly capital intensive. With only $8.9 million in cash against a full-year operating burn of $14.6 million, an equity raise appears imminent. The technology is derisked, but the balance sheet is not.
🐂 Bull Case
The FDA clearance bottleneck has been cleared. Q4 sales of $1.3M represent a sharp acceleration, and recent backing from the American Society of Breast Surgeons (ASBrS) will further grease the wheels for widespread U.S. adoption.
IceCure is cleverly structuring its FDA-mandated 'ChoICE' post-marketing study. The 30 planned clinical sites will also serve as active commercial centers, meaning study roll-outs will directly drive system placements and consumable revenue.
🐻 Bear Case
Cash and equivalents sit at $8.9 million. With FY25 operating cash burn at $14.6 million and management guiding for increased Sales & Marketing expenses in 2026, the company will likely need to raise capital soon, diluting current shareholders.
Full-year gross margins decelerated heavily to 36% from 44% in FY24, which management explicitly blamed on increased raw material, subcontractor, and auxiliary material costs. If pricing power cannot offset these macro supply chain pressures, scaling will remain unprofitable.
⚖️ Verdict: ⚪
Neutral. The commercial thesis is fully validated by the Q4 revenue spike and new medical society guidelines. However, a precarious cash position and an imminent need for funding keep the risk profile elevated.
Key Themes
Q4 Inflection: FDA Clearance Triggers Immediate Growth
After quarters of stagnant growth awaiting regulatory decisions, sales are explicitly accelerating. Following the October FDA clearance for ProSense in low-risk breast cancer, Q4 revenues jumped to ~$1.3M (up from $0.85M in Q3). Key prestigious U.S. hospital networks are successfully transitioning from the pipeline into installed commercial accounts.
ASBrS Recommendation Cements Standard of Care
In a massive win for commercialization, the American Society of Breast Surgeons (ASBrS) updated its 2026 resource guide to recommend cryoablation for selected low-risk breast cancer patients. This eliminates a major hurdle for hospital procurement committees and will likely accelerate the transition from early adopters to mainstream use.
Reimbursement Pathway Expanding
Reimbursement is stabilizing. Procedures currently benefit from a CPT III code covering approximately $4,000 in facility costs. IceCure plans to submit for a CPT I code in Q2 2026 (effective early 2028), and expects an additional $900 from Transitional Pass-Through (TPT) payments in early 2027, vastly improving unit economics for providers.
Cash Burn Outpacing Runway
Financial stability remains highly precarious. The company ended 2025 with $8.9M in cash and equivalents. FY25 cash used in operations was $14.6M. The company explicitly states that Sales & Marketing costs will increase in 2026 to support the U.S. launch, ensuring the cash burn will continue or accelerate. A dilutive financing event is almost a certainty.
Macro Inflation Hits Full-Year Gross Margins
Despite the Q4 volume-driven rebound, FY25 gross margins deteriorated significantly, coming in at 36% versus 44% in FY24. Management pointed to a specific macro concern: the rising cost of raw materials, auxiliary materials, and subcontractors. If these supply chain costs remain structurally high, IceCure will need to push through aggressive price hikes to return to historical 40%+ annual margins.
Execution Risk on the ChoICE Post-Market Study
While serving as a commercial catalyst, the FDA-mandated 'ChoICE' study is a heavy operational lift. The company must enroll 400 patients across 30 U.S. sites over 36 months, with a target of 80 patients in year one (starting H2 2026). Delays in site onboarding or patient recruitment could attract FDA scrutiny and delay wider CPT I reimbursement conversions.
Other KPIs
Decelerating year-over-year from $6.30 million in FY24. However, management explicitly notes this line item is reversing trend and will accelerate in 2026 as the company aggressively builds out its U.S. commercial infrastructure following the Q4 FDA clearance.
Accelerating slightly from $7.10 million in FY24. The increase was driven by clinical trial activity and payroll, partially offset by a reduction in development expenses for the next-generation XSense system.
Guidance
IceCure filed a Class III amendment in March 2026 to expand Canadian approval to low-risk breast cancer for women 60+. If approved, this targets a new addressable pool of up to 7,130 eligible women.
Partner Terumo Corporation is on track to file for regulatory approval of ProSense for breast cancer in Japan, opening up one of the largest international markets for the company's flagship indication.
Key Questions
Capital Raising Strategy
Given the current cash balance of $8.9 million against an anticipated increase in operating expenses for 2026, what is management's preferred timeline and structure (e.g., debt, equity, partnership milestones) for bolstering the balance sheet?
Gross Margin Sustainability
FY25 gross margins compressed to 36% due to raw material and subcontractor costs. Now that U.S. commercial volumes are scaling up, as seen in Q4, do you expect volume leverage to offset these supply chain headwinds and return margins to the mid-40s?
ChoICE Study Site Conversion
You plan to launch 30 hybrid commercial/clinical sites for the ChoICE study. How many of these 30 targeted sites have already signed procurement contracts for the ProSense system?